Eton Pharmaceuticals Acquires U.S. Rights to ASN-001 for Infantile Hemangiomas

Eton Pharmaceuticals has secured U.S. rights to ASN-001, expanding its portfolio for treating infantile hemangiomas. This acquisition could significantly impact patient care and revenue in the pediatric sector.